For active Australians who can't afford to compromise on what's in their system. A prescription wellbeing program — formulated, manufactured and dispensed entirely in Australia.
Clinically formulated · Australian made
Clinically formulated · Australian made
Australian medicinal cannabis sits inside one of the most rigorous regulatory frameworks in the world — and 2032CBD is built to operate at every link in that chain. Formulated by Australian clinicians. Manufactured under Australian standards. Dispensed by Australian pharmacists. Prescribed by Australian doctors.
A program designed by Australian medical practitioners to address Australian patient needs — under the oversight of the Therapeutic Goods Administration.
Production occurs within an Australian compounding pharmacy environment, with a path to GMP-grade manufacturing as the program scales.
Every prescription is filled by a registered Australian pharmacy with full chain-of-custody traceability from formulation to patient.
Schedule 4 prescription medicine accessed via the Therapeutic Goods Administration's Special Access Scheme. Every dispense is clinician-authorised and traceable.
Formulated to align with the World Anti-Doping Agency standard for permitted substances. For Australians whose livelihood — or licence — depends on what's in their system.
Designed to be compatible with workplace drug-screening protocols and roadside oral-fluid testing — for FIFO, defence, professional drivers, healthcare and parents on the school run.
Don't take our word for it. Take the certification.
Submit an interest form. Receive a unique secure login. Complete your profile, baseline survey and consent online — privately and at your own pace.
Once onboarding is complete, our clinical team contacts you to schedule a consultation with the prescribing physician — in person or via telehealth.
If clinically appropriate, your prescription is sent to our partner Australian pharmacy. Your supply is dispensed and delivered, or available for in-clinic collection.
Track your progress through the patient portal. Two-way messaging with the clinical team. Scheduled reviews. Continued supply only with clinician approval.
Dr Saul Geffen is a fellow of the Faculty of Pain Medicine and brings over two decades of specialist practice in chronic pain, rehabilitation and recovery medicine. He leads the clinical program for 2032CBD — overseeing patient assessment, prescribing protocols, formulation review and adverse-event monitoring.
The 2032CBD program is built around his clinical philosophy: that medicinal cannabis access in Australia must be evidence-driven, conservatively dosed, and properly supervised — not a replacement for primary care, but a complement to it.
Three ways to engage with the 2032CBD program. Pick the path that matches where you're at.
Your enquiry is in. The clinical team will be in touch via your preferred contact channel within two business days.
2032CBD is a Schedule 4 prescription medicine under the Therapeutic Goods Act. It is not available over the counter. Access is gated through registered Australian medical practitioners.
Prescriptions are issued under the TGA's SAS-B pathway, which permits Australian doctors to prescribe specific unapproved therapeutic goods to individual patients for whom the medicine is clinically indicated.
Every prescription is dispensed by a registered Australian pharmacy under the supervision of a pharmacist. Each batch carries a Certificate of Analysis viewable by your clinician.
Profile, baseline survey, consent, daily check-ins, surveys, batch certificates, two-way messaging with the clinical team.
Sign in →Patient cohort overview, pending bookings, outcomes analytics, batch QA, formulation panel, lead pipeline, adverse-event log, prescriber documentation.
Sign in →